Bullfrog AI Holdings Inc. (NASDAQ:BFRG) Shares Shorted: Short Interest Up 626.5% in September

Posted by Geri Gentry on Oct 11th, 2026

Bullfrog AI Holdings Inc. (NASDAQ:BFRG – Get Free Report) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totaling 739,209 shares, a growth of 626.5% from the September 15th total of 101,743 shares. Based on an average daily volume of 24,317,264 shares, the short-interest ratio is presently 0.0 days. Currently, 4.7% of the company’s stock are sold short.

Wall Street Analyst Weigh In

BFRG has been the topic of a number of recent analyst reports. Weiss Ratings upgraded shares of Bullfrog AI from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. Wall Street Zen upgraded shares of Bullfrog AI from a “sell” rating to a “hold” rating in a research note on Saturday, July 4th. Finally, Zacks Research upgraded shares of Bullfrog AI to a “hold” rating in a research note on Friday, June 26th. One analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Bullfrog AI presently has an average rating of “Reduce”.

Check Out Our Latest Stock Report on Bullfrog AI

Insider Buying and Selling

In related news, CFO Joshua Blacher purchased 50,000 shares of the firm’s stock in a transaction on Tuesday, September 22nd. The stock was purchased at an average cost of $0.53 per share, for a total transaction of $26,500.00. Following the completion of the purchase, the chief financial officer directly owned 65,000 shares in the company, valued at $34,450. This trade represents a 333.33% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Vininder Singh purchased 75,000 shares of the stock in a transaction on Tuesday, September 22nd. The shares were bought at an average cost of $0.60 per share, for a total transaction of $45,000.00. Following the transaction, the chief executive officer directly owned 2,442,446 shares in the company, valued at approximately $1,465,467.60. The trade was a 3.17% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. 14.70% of the stock is owned by company insiders.

Institutional Investors Weigh In On Bullfrog AI

A hedge fund recently bought a new stake in Bullfrog AI stock. Citadel Advisors LLC purchased a new stake in shares of Bullfrog AI Holdings Inc. (NASDAQ:BFRG – Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 361,546 shares of the company’s stock, valued at approximately $257,000. Citadel Advisors LLC owned about 1.95% of Bullfrog AI at the end of the most recent reporting period. 0.96% of the stock is owned by institutional investors.

Bullfrog AI Price Performance

NASDAQ BFRG traded down $0.05 during trading on Friday, reaching $0.65. 560,793 shares of the company’s stock were exchanged, compared to its average volume of 16,825,202. The business has a 50 day moving average price of $0.57 and a 200-day moving average price of $0.69. The stock has a market capitalization of $11.98 million, a P/E ratio of -1.40 and a beta of -2.73. Bullfrog AI has a fifty-two week low of $0.43 and a fifty-two week high of $1.96.

Bullfrog AI (NASDAQ:BFRG – Get Free Report) last released its quarterly earnings data on Friday, August 14th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.04. The business had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.21 million. On average, analysts forecast that Bullfrog AI will post -0.37 earnings per share for the current year.

About Bullfrog AI

(Get Free Report)

BullFrog AI Holdings, Inc is a technology company focused on applying artificial intelligence and machine learning to the medical and healthcare industries. The company develops tools intended to help organizations analyze complex biomedical and clinical data, identify patterns, and support research and decision-making.

Its primary platform, bfLEAP, is designed to provide advanced data analysis and predictive analytics for pharmaceutical and biotechnology companies, medical institutions, and other healthcare-related organizations.